Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2
Author:
Mateus-Seidl Rita1, Stahl Sebastian2, Dengl Stefan2, Birzele Fabian3, Herrmuth Hedda1, Mayer Klaus2, Niederfellner Gerhard1, Liu Xiu-Fen4, Pastan Ira4, Brinkmann Ulrich2
Affiliation:
1. Roche Pharma Research and Early Development , Discovery Oncology, Roche Innovation Center Munich , Nonnenwald 2 , D-82377 Penzberg, FRG , Germany 2. Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Munich , Nonnenwald 2 , D-82377 Penzberg, FRG , Germany 3. Roche Pharma Research and Early Development , Pharmaceutical Sciences- Bioinformatics, Roche Innovation Center Basel , Grenzacherstr. 124 , CH-4070 Basel , Germany 4. Laboratory of Molecular Biology , Center for Cancer Research, National Cancer Institute, National Institutes of Health , 37 Convent Dr , Bethesda, MD 20814 , USA
Abstract
Abstract
The functionality of eukaryotic translation elongation factor 2 (eEF2) is modulated by phosphorylation, eEF2 is simultaneously the molecular target of ADP-ribosylating toxins. We analyzed the interplay between phosphorylation and diphthamide-dependent ADP-ribosylation. Phosphorylation does not require diphthamide, eEF2 without it still becomes phosphorylated. ADP-ribosylation not only modifies the H715 diphthamide but also inhibits phosphorylation of S595 located in proximity to H715, and stimulates phosphorylation of T56. S595 can be phosphorylated by CDK2 and CDK1 which affects EEF2K-mediated T56-phosphorylation. Thus, ADP-ribosylation and S595-phosphorylation by kinases occur within the same vicinity and both trigger T56-phosphorylation. Diphthamide is surface-accessible permitting access to ADP-ribosylating enzymes, the adjacent S595 side chain extends into the interior. This orientation is incompatible with phosphorylation, neither allowing kinase access nor phosphate attachment. S595 phosphorylation must therefore be accompanied by structural alterations affecting the interface to ADP-ribosylating toxins. In agreement with that, replacement of S595 with Ala, Glu or Asp prevents ADP-ribosylation. Phosphorylation (starvation) as well as ADP-ribosylation (toxins) inhibit protein synthesis, both affect the S595/H715 region of eEF2, both trigger T57-phosphorylation eliciting similar transcriptional responses. Phosphorylation is short lived while ADP-ribosylation is stable. Thus, phosphorylation of the S595/H715 ‘modifier region’ triggers transient interruption of translation while ADP-ribosylation arrests irreversibly.
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference30 articles.
1. Balasubramanian, M., Shan, J., and Kilberg, M. (2013). Dynamic changes in genomic histone association and modification during activation of the ASNS and ATF3 genes by amino acid limitation. Biochem. J. 449, 219. 2. Chen, Z., Gopalakrishnan, S.M., Bui, M.H., Soni, N.B., Warrior, U., Johnson, E.F., Donnelly, J.B., and Glaser, K.B. (2011). 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J. Biol. Chem. 286, 43951–43958. 3. Dong, M., Su, X., Dzikovski, B., Dando, E.E., Zhu, X., Du, J., Freed, J.H., and Lin, H. (2014). Dph3 Is an electron donor for Dph1-Dph2 in the first step of eukaryotic diphthamide biosynthesis. J. Am. Chem. Soc. 136, 1754–1757. 4. Hassan, R., Alewine, C., and Pastan, I. (2016). New life for immunotoxin cancer therapy. Clin. Cancer Res. 22, 1055. 5. Hizli, A.A., Chi, Y., Swanger, J., Carter, J.H., Liao, Y., Welcker, M., Ryazanov, A.G., and Clurman, B.E. (2013). Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase. Mol. Cell. Biol. 33, 596.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|